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Isabel Sanchez-Ortega,1,2 Octavio Servitje,3,4 Montserrat Arnan,1,4 Guillermo Ortı,1,4
Teresa Peralta,1,4 Federico Manresa,4,5 Rafael F. Duarte1,4Sclerotic chronic graft-versus-host disease (scGVHD) is a severe form of this disease that resembles systemic
sclerosis and has limited and disappointing treatment options. Tyrosine kinase inhibitors (TKI) targeting
up-regulated profibrotic pathways, such as imatinib mesylate, have been proposed as a potential therapeutic
approach for patients with scGVHD. Dasatinib, a second-generation TKI with a well-established safety and
efficacy profile in chronic myeloid leukemia patients, who are refractory or intolerant to imatinib, has also
shown potent antifibrotic effects. We present here the first direct clinical evidence, from 3 patients treated
in a small single-center series, suggesting that dasatinib can be a therapeutic option for patients with severe
scGVHD resistant or intolerant to imatinib. All patients achieved partial response, with improvement in
scGHVD target organs severity, joint mobility, lung impairment, and deep fibrotic lesions. This clinical
response has remained stable or continued to improve after a median of 22 months (20-25) on dasatinib
treatment, with very good tolerance. In addition, corticosteroids could be discontinued or significantly re-
duced in all patients. This clinical evidence suggests that dasatinib could be a safe and effective alternative for
scGVHD patients refractory to corticosteroids and resistant or intolerant to imatinib. Based on these pre-
liminary findings, and in order to address appropriate patient selection, time of intervention, and choice of
drug, future larger studies shouldmore formally establish the efficacy and safety of second-generation TKI for
the treatment of scGVHD.
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Chronic graft-versus-host disease (cGVHD) is the
major cause of late nonrelapse morbidity andmortality
after allogeneic blood and marrow transplantation
(alloBMT) [1,2]. Sclerotic chronic (sc) GVHD is 1 of
the most severe forms of this disease, characterized
by excess collagen production by activated
fibroblasts, which resembles systemic sclerosis and
is frequently refractory to standard treatment
approaches [3]. Imatinib mesylate (IM) is a tyrosine
kinase inhibitor (TKI) successfully used in patients
with Bcr-Abl-positive leukemias [4,5]. In addition to
its anti-Bcr-Abl effect, IM exerts a strong antifibrotic
activity through inhibition of transforming growth
factor-b and platelet-derived growth factor signaling1Department of Clinical Hematology, Catalan Institute of
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isclosure: See Acknowledgments on page 323.pathways, which are key in the pathogenesis of fibrotic
diseases like scGVHD [6-10]. Based on these data,
several case reports and 2 initial series explored the
use of IM as a novel therapeutic option for patients
with scGVHD, and showed that up to 50% to 79%
of these patients improve with this agent [11-14].
Nevertheless, one-third to one-half of patients with
scGVHD treated with IM fail to respond or are intol-
erant to treatment.
Second-generation TKI have a greater inhibitory
potency and a better tolerability profile than IM, and
have been approved for the treatment of chronic
myeloid leukemia (CML) patients who are refractory
or intolerant to IM [15]. Dasatinib is a second-
generation multikinase inhibitor, which, beyond its
antileukemic effect, targets not only transformingCorrespondence and reprint requests: Rafael F. Duarte, MD, PhD,
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receptor profibrotic signaling pathways, but also Src
kinases, which play an important role in the develop-
ment of experimental dermal fibrosis [16], and which
have been shown to effectively inhibit the synthesis
of extracellular matrix in both in vitro and in vivo
models [17]. We hypothesized that dasatinib may be
a therapeutic alternative for scGVHD. Here, we pro-
vide the first direct clinical evidence suggesting that
dasatinib can indeed be a safe and effective therapeutic
option for patients with severe scGVHD refractory to
corticosteroids and resistant or intolerant to IM.METHODS
We describe a single-center series of 3 patients
with severe scGVHD who received salvage therapy
with dasatinib after failing several previous lines of
systemic therapy including corticosteroids and IM.
Patient characteristics are summarized in Table 1.
Hospital approval and informed consent for off-label
use of the drug were obtained in all cases. Patients
also signed and agreed for their data and images to
be used to illustrate their clinical response in this
paper. Dasatinib was started at a dose of 50 mg daily,
and then escalated to 100 mg daily within 8 weeks in
the absence of severe toxicity or intolerance. Adverse
events were graded according to Common Terminol-
ogy Criteria for Adverse Events, Version 3.0. Support-
ive care and antimicrobial prophylaxis and monitoring
followed our standard protocols in keeping with inter-
national guidelines [18]. Diagnoses other than
scGVHD, including infections and drug reactions,
were previously excluded, and in all cases scleroderm-
atous features were histologically confirmed by skin
biopsy (data not shown). Diagnosis and staging of
scGVHD were assessed according to the National
Institutes of Health Consensus Conference on
cGVHD [19].
Before initiating dasatinib treatment, patients were
carefully examined to determine their skin score, ulcer
size, joint mobility, range of motion, Zubrod perfor-
mance status, and evaluation of any other possible
site involvement. Response to therapy was graded
according to the criteria proposed by Couriel et al.
[20]. Complete response was defined as resolution of
all manifestations of cGHVD. Partial response was de-
fined as at least 50% improvement in the affected site,
as follows: for skin involvement, reduction $50% of
body surface area involved by nonmoveable sclerosis,
erythematous rash, and/or ulcers and improvement
in Zubrod status by 1; for lung, sustained improvement
in pulmonary function tests and/or steroid tapering by
50% without deterioration of pulmonary function.
Additionally, joints and fascia partial response was de-fined as any improvement in range of motion and re-
duction in the National Institutes of Health score by
1 or more [19], without achieving complete response.
Response in every affected site and global cGVHD
score were prospectively evaluated at 3 monthly inter-
vals from the start of treatment.RESULTS AND DISCUSSION
All 3 patients treated with dasatinib in this series
were resistant and/or intolerant to IM, and had addi-
tionally failed at least 3 previous systemic immunosup-
pressive lines, including refractoriness to first-line
corticosteroids [2]. Before the start of dasatinib treat-
ment, they all had severe sclerotic features including
deep tissue sclerosis, joints contracture, severe mobil-
ity restriction, and functional impairment, as summa-
rized in the scores and images in Table 1 and
Figure 1. Patient #1 had a de novo scGVHD onset 9
months after a nonmyeloablative alloBMT. Despite
initial treatment with prednisone (2 mg/kg) and cyclo-
sporine A (CyA), and subsequent addition of mycophe-
nolate mofetil (MMF), features of scGVHD continued
to progress over the following months. She developed
severe lung involvement with bronchiolitis obliterans
confirmed in chest CT scans and pulmonary function
tests that made her dependent on domiciliary-
oxygen. Five months after the onset of scGVHD, IM
(400 mg daily) was added to the treatment. While on
IM, the features of scGVHD stabilized, but the patient
remained oxygen dependent. After several months, the
patient started experiencing gastrointestinal intoler-
ance and grade 3-4 cytopenias requiring growth factor
support, which would not allow escalation of the dose
of IM. Eight months after initiation, IMwas discontin-
ued, based on intolerance and suboptimal response,
and dasatinib was started. At this point the patient
remained oxygen-dependent with no significant clini-
cal improvement, and was still on CyA, MMF, and 1
mg/kg prednisone. Patient #2 had a quiescent
scGVHD onset 5 months after an HLA-identical re-
lated-donor myeloablative alloBMT. An initial partial
response was achieved with corticosteroids, CyA, and
MMF. He subsequently received 10 doses of PUVA,
which allowed tapering of corticosteroids first and
CyA next, but had to be stopped as a result of skin in-
tolerance. Two years later, ongoing sclerotic features
progressed, with severe nail dystrophy, painful ulcers
(Figure 1A), skin hypopigmentation, and nonscarring
alopecia. Treatment with IM was tried for 3 months
before switching to dasatinib for gastrointestinal intol-
erance and absence of clinical response. Patient #3 had
de novo scGVHD onset 10 months after a myeloabla-
tive, unrelated donor alloBMT. Despite treatment
with corticosteroids, CyA, and MMF, sclerotic fea-
tures progressed along with generalized pruritus,
Table 1. Patient, Transplant, and scGVHD Characteristics and Response to Treatment with Dasatinib
Patient #1 Patient #2 Patient #3
Sex Female Male Female
Age at alloBMT 58 28 27
Disease and status at alloBMT First CR AML First CR AML First CR AML
Conditioning regimen RIC (Flu-Bu) MAC (Cy-TBI) MAC (Cy-TBI)
GVHD prophylaxis CyA, MTX CyA, MTX CyA, MTX, ATG*
Donor relation; HLA matching Related; 10/10 Related; 10/10 Unrelated; 10/10
Stem cell source PB PB PB
Date of alloBMT September 2007 April 2007 January 2008
Acute GvHD – Cutaneous grade III on day + 42; Responsive to CS –
cGVHD onset, date
(months from BMT)
De novo, June 2008 (9) Quiescent, September 2007 (5) De novo, November 2008 (10)
Main cGVHD targets Skin, joints, and lungs Skin, joints, nails, hair, mouth, and eyes Skin, joints, and nails
Lines of systemic IS before IM CyA, MMF, CS CyA, MMF, CS, PUVA CyA, MMF, CS
Off-label indication for dasatinib use IM intolerant (GI and cytopenias) and suboptimal response IM intolerant (GI) and resistant to IM Resistant to IM (progressive scGVHD)
Start of dasatinib treatment July 2009 December 2009 October 2009
Months from alloBMT 22 32 21
Months from scGVHD onset 13 26 11
Months from start of IM 8 3 4
Months on dasatinib
(last follow up in August 2011)
25 20 22
NIH SCORES PRE POST (12 months) PRE POST (6 months) PRE POST (12 months)
cGVHD overall score Severe Severe Severe Moderate Severe Moderate
Performance Status: Zubrod
(Karnofsky)
3 (50%) 2 (70%) 2 (60%) 1 (80%) 2 (60%) 1 (90%)
Joints and fascia, NIH score 2 1 3 1 3 1
Decreased range of motion Shoulders, elbow Upper extremities Left lower extremity,
upper extremities
Skin, NIH score
Longest diameter of largest ulcer
(location)
3
Generalized liquenoid
changes; deep sclerosis
(neck, axillas, forearms)
3
Improvement in sclerotic
features and mobility
3
Deep slcerotic features
(neck, axillas, hips)
2
Superficial sclerosis
(not hidebound)
3
Deep sclerosis (arms, forearms,
lower extremities) and facial
hyperpigmentation
2
Superficial sclerosis
(not hidebound).
Changes in skin
pigmentation in Figure 1.
2 cm
Back
No ulcer 3.6 cm
Neck
No ulcer (see Figure 1) No ulcer No ulcer
Lung; NIH score (LFS) 3 (11) 2 (9) 0 0 0 0
Percent CS reduction
Current prednisone dosage/day
93%
10 mg
100%
0
100%
0
Status at last follow-up
(August 2011)
Alive, CR 47 months after alloBMT Alive, CR 52 m after AlloBMT Alive, CR 43 m after AlloBMT
PRE indicates scGVHD assessment according to National Institutes of Health (NIH) scoring before initiating; dasatinib treatment; POST, scGVHD asses nt according to NIH scoring at best response (months after
initiation of dasatinib treatment); IS, immunosuppression; LFS, lung function score (LFS5 FEV1 score + DLCO score according to NIH; Scale 2 to 12); C rticosteroids; CR, complete remission; AML, acute myeloid
leukemia; RIC, reduced intensity conditioning; Flu, fludarabine; Bu, busulphan; ATG, antithymocyte globulin; MAC, myeloablative conditioning; Cy, cyclo sphamide; TBI, total body irradiation; MTX, methrotexate;
PB, peripheral blood; PUVA, Psolaren-UV-A therapy; GI, gastrointestinal.
*ATG (antithymocyte globulin; Thymoglobulin): 2 mg/kg/day on days 23 to 21.
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Figure 1. Response of skin scGVHD to dasatinib treatment. Patient #2: neck ulcers of 3.6 cm and 1.7 cm in diameter before initiating dasatinib treat-
ment (A) and at 3 months (B). Patient #3: skin hyperpigmentation before initiating dasatinib treatment (C) and at 12 months (D).
Biol Blood Marrow Transplant 18:309-329, 2012 321Dasatinib for Refractory scGVHDskin ulcers fromminor trauma, progressive skin hyper-
pigmentation (Figure 1C), and restriction of joint mo-
bility, including severe left knee contracture lacking 20
degrees of extension, which caused a significant limita-
tion in the range of motion of the left leg and the pa-
tient’s capacity to walk normally. Disease continued
to progress for 4 months of IM therapy before
dasatinib was started.
Treatment change to dasatinib was tolerated well
in all cases, allowing dose-escalation from 50 mg to
100mgwithin 8weeks, as scheduled. At the time of first
response assessment, 3 months after the start of dasati-
nib, all patients had experienced disease response.
Patients #1 and #2 had already achieved partial re-
sponses, with objective improvement in target organs
severity, regression of deep sclerotic features in terms
of body surface area involved by hidebound lesions,
skin thickness, and ulceration (Figure 1B), along with
improved joint motility and function. Patient #2, also
showed resolution of photophobia and improvement
of his dry eye symptoms, which allowed discontinua-
tion of his eyedrops, as well as disappearance of mouth
mucosal ulcers and improvement of his sensitive and
dry mouth symptoms. Patient #1 also showed an initial
improvement of her pulmonary involvement, and by 12months of dasatinib treatment she became oxygen-
independent at rest while undergoing a greater than
90% reduction of her initial corticosteroid dose
(Table 1). After 3 months of dasatinib therapy, patient
#3 achieved initial stabilization of her sclerotic features,
which had been in frank progression under IM.
Six months later, she started progressive clinical and
functional improvement. By 12 months, she achieved
a partial response, including resolution of her hyper-
pigmented skin lesions (Figure 1D) and full normaliza-
tion of her left lower extremity range of motion,
becoming again able to walk normally, with her func-
tional disability almost normalized (Table 1).
At the most recent follow-up, patients have been
on dasatinib for scGVHD for a median of 22 months
(20-25). The safety of dasatinib in this setting has
remained very good, with no observed grade 3-4
adverse events, and minor grade 1-2 adverse events
(Table 2), which did not require treatment discontinu-
ation or dose adjustment. All patients are alive and in
complete remission of their primary disease at amedian
of 47 months after transplantation (43-52). Patient #1
remains on a stable partial response of her scGVHD
on dasatinib and with her corticosteroid dose down
to 0.16 mg/kg of oral prednisone. Patients #2 and #3
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322 Biol Blood Marrow Transplant 18:309-329, 2012I. Sanchez-Ortega et al.are both off corticosteroids and continue to show
further clinical improvement.
First- and second-generation TKI offer an exciting
new avenue for treatment of patients with severe
scGVHD. Their well-established safety profile is par-
ticularly suitable for such heavily immunosuppressed
patients, many of whom die from the associated sus-
ceptibility to infections induced by multiple lines of
immunosuppressive drugs [1]. Breccia et al. [21] have
reported indirect evidence in a patient treated with
low-dose dasatinib for a CML relapse after
haploidentical BMT: that the drug may have an immu-
nomodulatory effect over hepatic cGVHD. Our expe-
rience in alloBMT recipients for Bcr-Abl-negative
leukemias provides the first direct clinical evidence to
suggest that treatment with dasatinib may indeed be
a safe and effective therapeutic alternative for patients
with severe scGVHD refractory to standard therapy.
Our 3 cases improved their scGVHD severity score
in target organs, remarkably including severe lung im-
pairment and joint restrictions. This clinical response
has remained stable or continued to improve in all 3
cases after a median of nearly 2 years on dasatinib
treatment, with good tolerance. This allowed us to dis-
continue corticosteroids in 2 cases and to reduce to
\10% of the initial dose in the third case. The com-
plexity of the pathophysiology underlying scGVHD
and our limited understanding of the mechanisms of
action and the factors predicting success of the use of
TKI in this setting is emphasized by an interesting
case reported by Pulanic et al. [22] where an alloBMT
recipient developed severe scGVHD while on treat-
ment with dasatinib for persistence of residual CML
after transplant. On the other hand, although dasatinib
was first approved for CML only in patients who were
resistant or intolerant to IM, recent studies have shown
that first-line dasatinib treatment does induce signifi-
cantly higher and faster response rates than IM [23].
Based on this evidence in CML, one may hypothesize
that dasatinib may be a preferable first-line TKI to IM
also for scGVHD, in particular, considering the
severity and high rates of morbidity and mortality of
this disease. Our preliminary experience suggests
that dasatinib is a safe and effective therapeutic option
for patients with severe scGVHD refractory to
corticosteroids and resistant or intolerant to IM.
Despite these early responses and encouraging find-
ings in our series, a noncomparative design cannot for-
mally exclude, for instance, disease evolution over time
rather than continuous effect of dasatinib therapy to be
responsible for longer term improvement. Many addi-
tional questions remain, and future larger studies
should more formally establish the efficacy and safety
of second-generation TKI for the treatment
scGVHD, as well as help us address appropriate pa-
tient selection, optimal time of intervention, and
choice of drug.
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